Background macular Shape Background macular Shape Background macular Shape
Grants > Linkage and Association Studies for Macular Degeneration Updated On: Ene. 21, 2025
Macular Degeneration Research Grant

Linkage and Association Studies for Macular Degeneration

Principal Investigator

Michael Gorin, MD, PhD

Jules Stein Eye Institute at UCLA

Los Angeles, CA, USA

About the Research Project

Program

Macular Degeneration Research

Award Type

Standard

Award Amount

$150,000

Active Dates

April 01, 2006 - March 31, 2010

Grant ID

M2006004

Co-Principal Investigator(s)

Daniel Weeks, PhD, University of Pittsburgh

Yvette Conley, PhD, University of Pittsburgh

Goals

We are investigating the genetic variations that contribute to ARM so that we can eventually understand the causes of this complex condition. We study the genetic variations that are shared among ARM-affected individuals within families as well as compare the frequencies of genetic variations in ARM-affected individuals with those in unaffected persons who are matched in age, gender, and exposures.

Summary

Age-related macular degeneration (ARM) is a major cause of vision loss in the elderly. It is thought that smoking and diet may contribute to the risk of developing the condition, but it is clear that heredity plays a major role. Variations in two genes, CFH and PLEKHA1/LOC387715, have been found to strongly contribute to the risk of developing ARM, but there are additional genes that probably influence a person’s chances of having this condition and how they will progress to vision loss. We are investigating the genetic variations that contribute to ARM so that we can eventually understand the causes of this complex condition. We study the genetic variations that are shared among ARM-affected individuals within families as well as compare the frequencies of genetic variations in ARM-affected individuals with those in unaffected persons who are matched in age, gender, and exposure. Our long-term goals are to develop new preventive therapies that can slow or halt the development of this disease and to be able to provide these treatments to those who are at greatest risk before they experience vision-threatening changes.